Last reviewed · How we verify
Infanrix® Penta
Infanrix Penta is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.
Infanrix Penta is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b. Used for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.
At a glance
| Generic name | Infanrix® Penta |
|---|---|
| Also known as | DTPa-HBV-IPV vaccine, DTPa-HBV-IPV (GSK Biologicals)., Pediarix |
| Sponsor | GlaxoSmithKline |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease Prevention |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, inactivated poliovirus, and conjugated Haemophilus influenzae type b polysaccharide. These components trigger adaptive immune responses, generating specific antibodies and cellular immunity against these five pathogens, providing protection against the corresponding infectious diseases.
Approved indications
- Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability
- Drowsiness
- Loss of appetite
Key clinical trials
- Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine (PHASE2)
- 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age (PHASE2)
- Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines (PHASE2)
- Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants (PHASE2)
- Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |